Credit Suisse Group reaffirmed their buy rating on shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in a research note issued to investors on Friday. The firm currently has a $485.00 price target on the biopharmaceutical company’s stock.
Several other equities analysts have also commented on the stock. RBC Capital Markets set a $626.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a buy rating in a research report on Monday, December 5th. Leerink Swann set a $513.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a buy rating in a research report on Tuesday, October 25th. Roth Capital set a $520.00 target price on shares of Regeneron Pharmaceuticals and gave the company a buy rating in a research note on Friday, October 28th. Vetr raised shares of Regeneron Pharmaceuticals to a buy rating in a research note on Monday, November 21st. Finally, Canaccord Genuity set a $450.00 target price on shares of Regeneron Pharmaceuticals and gave the company a hold rating in a research note on Friday, February 3rd. Twelve research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. Regeneron Pharmaceuticals currently has an average rating of Buy and an average price target of $447.20.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 359.87 on Friday. The company has a 50 day moving average of $363.18 and a 200-day moving average of $386.48. Regeneron Pharmaceuticals has a 12-month low of $325.35 and a 12-month high of $452.96. The firm has a market cap of $37.83 billion, a price-to-earnings ratio of 46.74 and a beta of 1.44.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, February 9th. The biopharmaceutical company reported $3.04 EPS for the quarter, beating the Zacks’ consensus estimate of $3.03 by $0.01. Regeneron Pharmaceuticals had a net margin of 18.10% and a return on equity of 22.51%. The business earned $1.23 billion during the quarter, compared to analysts’ expectations of $1.30 billion. During the same period in the prior year, the company earned $2.83 earnings per share. The firm’s revenue was up 11.7% on a year-over-year basis. Analysts predict that Regeneron Pharmaceuticals will post $13.25 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This news story was reported by sleekmoney and is owned by of sleekmoney. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at http://sleekmoney.com/regeneron-pharmaceuticals-inc-regn-receives-buy-rating-from-credit-suisse-group/1658100.html.
In related news, Director Charles A. Baker sold 3,000 shares of the stock in a transaction on Monday, December 12th. The stock was sold at an average price of $392.02, for a total transaction of $1,176,060.00. Following the completion of the sale, the director now directly owns 12,000 shares of the company’s stock, valued at $4,704,240. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Sanofi purchased 87,298 shares of the firm’s stock in a transaction that occurred on Wednesday, January 11th. The shares were bought at an average cost of $369.71 per share, with a total value of $32,274,943.58. The disclosure for this purchase can be found here. 10.40% of the stock is currently owned by corporate insiders.
Several large investors have recently modified their holdings of the company. IFP Advisors Inc boosted its position in Regeneron Pharmaceuticals by 32.3% in the second quarter. IFP Advisors Inc now owns 328 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 80 shares during the last quarter. Alpha Windward LLC boosted its position in Regeneron Pharmaceuticals by 11.6% in the third quarter. Alpha Windward LLC now owns 326 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 34 shares during the last quarter. NEXT Financial Group Inc boosted its position in Regeneron Pharmaceuticals by 46.9% in the third quarter. NEXT Financial Group Inc now owns 360 shares of the biopharmaceutical company’s stock valued at $145,000 after buying an additional 115 shares during the last quarter. Live Your Vision LLC acquired a new position in Regeneron Pharmaceuticals during the third quarter valued at about $157,000. Finally, Global X Management Co. LLC boosted its position in Regeneron Pharmaceuticals by 212.7% in the third quarter. Global X Management Co. LLC now owns 419 shares of the biopharmaceutical company’s stock valued at $168,000 after buying an additional 285 shares during the last quarter. 68.83% of the stock is owned by hedge funds and other institutional investors.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/regeneron-pharmaceuticals-inc-regn-receives-buy-rating-from-credit-suisse-group/1658100.html
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.